Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Blood Adv. 2024 May 28;8(10):2400-2404. doi: 10.1182/bloodadvances.2023011030.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brentuximab Vedotin* / therapeutic use
  • Female
  • Humans
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Lymphoma, T-Cell, Cutaneous* / pathology
  • Lymphoma, T-Cell, Peripheral* / drug therapy
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Nivolumab* / administration & dosage
  • Nivolumab* / therapeutic use
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology